Aurisco Pharmaceutical Co.,Ltd.

SHSE:605116 Stock Report

Market Cap: CN¥8.6b

Aurisco PharmaceuticalLtd Valuation

Is 605116 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 605116 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 605116 (CN¥21.12) is trading above our estimate of fair value (CN¥9.96)

Significantly Below Fair Value: 605116 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 605116?

Key metric: As 605116 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 605116. This is calculated by dividing 605116's market cap by their current earnings.
What is 605116's PE Ratio?
PE Ratio25.2x
EarningsCN¥340.67m
Market CapCN¥8.58b

Price to Earnings Ratio vs Peers

How does 605116's PE Ratio compare to its peers?

The above table shows the PE ratio for 605116 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average63.1x
300705 Hunan Jiudian Pharmaceutical
22.6x25.5%CN¥11.5b
300049 Inner Mongolia Furui Medical Science
74.6x47.1%CN¥9.7b
300181 Zhejiang Jolly PharmaceuticalLTD
22x23.3%CN¥11.4b
600771 GuangYuYuan Chinese Herbal Medicine
133.1xn/aCN¥9.3b
605116 Aurisco PharmaceuticalLtd
25.2x27.4%CN¥8.6b

Price-To-Earnings vs Peers: 605116 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the peer average (63.1x).


Price to Earnings Ratio vs Industry

How does 605116's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
605116 25.2xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 605116 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the CN Pharmaceuticals industry average (29.6x).


Price to Earnings Ratio vs Fair Ratio

What is 605116's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

605116 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.2x
Fair PE Ratio28.8x

Price-To-Earnings vs Fair Ratio: 605116 is good value based on its Price-To-Earnings Ratio (25.2x) compared to the estimated Fair Price-To-Earnings Ratio (28.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies